DeCure for Maturity-onset diabetes of the young type 10
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for maturity-onset diabetes of the young type 10 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMaturity-onset diabetes of the young type 10 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for maturity-onset diabetes of the young type 10 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
insulin (INS) — INS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hc4drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6TC2 · 1.36 Å · ligand 4'-HYDROXYCINNAMIC ACID (HC4). Experimental structure, not a prediction.
What the evidence adds up to
Maturity-onset diabetes of the young (MODY) accounts for only 1%–2% of all diabetes and is often misdiagnosed as type 1 or type 2 diabetes. Diagnosis allows individualised care based on the genetic cause. Two forms were identified by 1995: one linked to chromosome 20q, the other to glucokinase gene mutations on chromosome 7p. A 2025 report describes a new subtype from India, MODY 15, but provides no data on treatment or outcomes.
No abstract in this set reports a drug tested specifically in MODY type 10. One 2012 case series tested acetyl-L-carnitine (50 mg/kg/day) plus nicotinamide (25 mg/kg/day) in nine children at risk of type 1 diabetes, not MODY. During treatment, four patients recovered their metabolic parameters and medication was stopped; two continued with favourable evolution; two evolved slowly with normal growth and development; one girl became diabetic because she was treated late. The authors conclude the combination delays or remits type 1 diabetes evolution in at-risk children, but the sample is tiny, there is no blinding, and the treatment was not randomised against a proper control group.
A separate 2007 analysis of 6,123 children with type 1 diabetes found that partial remission (insulin <0.5 U/kg/day and HbA1c ≤7.0%) occurred in 32.5% within the first three months, lasting on average 0.74 years. Remission was shorter in children under 10 years and longer in boys and those with pubertal onset. These data are from type 1 diabetes, not MODY, and cannot be extrapolated.
What is still missing for MODY type 10 specifically: any clinical trial of any drug, any natural history study with treatment outcomes, any validated biomarker for patient stratification, and dedicated funding for a disease so rare that even its existence as a distinct subtype was only reported in 2025.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diabetes Metabolic Syndrome and Obesity · 2012 · 144 citations · open access
Clinical features and treatment of maturity onset diabetes of the young (MODY)
AbstractMaturity onset diabetes of the young (MODY) is a heterogeneous group of disorders that result in β-cell dysfunction. It is rare, accounting for just 1%-2% of all diabetes. It is often misdiagnosed as type 1 or type 2 diabetes, as it is often difficult to distinguish MODY from these two forms. However, diagnosis allows appropriate individualized care, depending on the genetic etiology, and allows prognostication in family members. In this review, we discuss features of the common causes of MODY, as well as the treatment and diagnosis of MODY.
Shorter Remission Period in Young Versus Older Children with Diabetes Mellitus Type 1
AbstractBACKGROUND: The initial period of diabetes type 1 is of great importance, since early metabolic adjustment has profound impact on long term control. The majority of pediatric centers in Germany participate in a national quality initiative, providing longitudinal data for central analysis. PATIENTS: 104543 anonymous data sets were obtained from 6123 pediatric patients under 18 years who were treated in 157 pediatric centers and monitored for 36 months at the same center starting from diagnosis. RESULTS: Partial remission (insulin <0.5 U/kg/d and HbA1c < or = 7.0%) was present in 1992 children (32.5%) within the first 3 months after diagnosis. Remission phase lasted in average for 0.74 +/- 0.77 years and was significantly shorter in children below 10 years of age at onset of diabetes compared to the older patients. The remission period was significantly longer in boys, particularly in children under 10 years (p=0.0039). Multiple regression analysis showed a longer remission phase in children with pubertal diabetes onset. The children entering remission were younger, more often boys and had a lower initial HbA1c level. CONCLUSION: These data from a large multicenter group of children with diabetes type 1 emphasize the influence of gender, pubertal stage and age at manifestation on the amount of insulin required, and therefore the clinical remission, during the first three years of the disease.
Current Opinion in Endocrinology & Diabetes · 1995 · 9 citations
Maturity-onset diabetes of the young
AbstractMaturity-onset diabetes of the young (MODY) is a subtype of non-insulin-dependent diabetes characterized by an early age of onset and an autosomal dominant inheritance. Thus far, two forms of MODY have been identified. One is tightly linked to genetic markers on chromosome 20q and the other is due to various mutations of the glucokinase. gene on chromosome 7p. These two forms of MODY are compared with regard to their phenotypic expression and their differences in insulin secretory defects. Further progress in our understanding of the molecular genetic and pathophysiologic aspects of various forms of MODY may advance our understanding of the nature of more common types of non-insulin-dependent diabetes mellitus.
Journal of Pediatric Endocrinology and Metabolism · 2012 · 6 citations
Children at risk of diabetes type 1. Treatment with acetyl-L-carnitine plus nicotinamide – Case reports
AbstractUNLABELLED: Abstract Objectives: The aim was to evaluate the treatment with acetyl-L-carnitine (50 mg/kg/day) and nicotinamide (25 mg/kg/day) in children at risk of type 1 diabetes. This treatment was effective and harmless in experimental type 1 diabetes in mice. PATIENTS: Nine out of seventy healthy participants of the type 1 diabetes risk study were treated. They were typified for diabetes with HLA-DQB1 and positive autoantibodies. Children with a first peak of insulin response ≤48 µU were randomly distributed in control and treated patients. Children evolution was followed with an intravenous glucose tolerance test. Control children were treated when was another risk parameter was added. During their evolution all children were treated. RESULTS: Treatment periods differ (range: 120-16 months) because children began treatment at different times. During the treatment 4 patients recovered their parameters and the medication was suspended; 2 patients continued the treatment with favorable evolution. Two children evolved slowly with normal growth and development. One girl became diabetic because she was treated late. CONCLUSIONS: In children at risk, this treatment delays the development or remits the evolution of type 1 diabetes.
Journal of the Association of Physicians of India · 2025 · 1 citations
Exciting Discovery of a New Maturity-onset Diabetes of the Young Subtype from India (MODY 15)
AbstractAt that time, the classification of diabetes was based purely on the age at onset of diabetes. Those diagnosed with diabetes below 40 years of age were labeled as "growth onset diabetes," while those with onset at or above the age of 40 years were referred to as "maturity onset diabetes." At that time, these types were believed to be equivalent to what are known as type 1 diabetes (T1D) and type 2 diabetes (T2D) today.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
